Study design
Post hoc analysis in patients treated with either T/O 5/5 μg or tio 5 μg (delivered via Respimat®) in two replicate, 52-week, parallel-group, double-blind studies (TONADO® 1 [NCT01431274] and TONADO® 2 [NCT01431287])
- The time to first occurrence of one of these events was recorded as the time to clinical deterioration
Abbreviations: COPD, chronic obstructive pulmonary disease; CID, clinically important deterioration; FEV1, forced expiratory volume in 1 second; SGRQ, St. George’s Respiratory Questionnaire; T/O, tiotropium/olodaterol; tio, tiotropium.